Core Product Advantages

1. High Efficiency and Accuracy

   Adopts high-precision next-generation sequencing technology for comprehensive detection of hereditary tumor-related genes, with high detection sensitivity and accuracy in identifying gene variations; the whole detection and analysis process is efficient, ensuring reliable test results for clinical tumor diagnosis and risk assessment.

2. Authoritative Guidance

   Covers genes and tumor types based on authoritative guidelines, databases and literature research, and interprets the pathogenicity of detected variations strictly in accordance with ACMG guidelines; the test results provide professional and authoritative genetic reference for hereditary tumor risk judgment and clinical decision-making.

3. Convenient Operation

   Features a streamlined and standardized detection process, with simple and easy-to-implement steps from informed consent and sample collection to sequencing and reporting; the operation is convenient for clinical institutions to carry out, adapting to large-scale screening and personalized detection needs of different populations.

Key Detection Content

Applicable Population

1. Tumor patients
   • Suffering from high-incidence hereditary tumors such as breast cancer, ovarian cancer and colorectal cancer
   • With early onset age, multiple lesions or multiple primary malignant tumors
   • Suffering from special tumor types (e.g., male breast cancer)
   • With a family history of tumors
2. People with a family history of tumors
   • Multiple relatives suffering from the same or similar tumors
   • Tumor cases involving at least two consecutive generations of relatives
   • Having young or special-type tumor patients in the family
3. General population: All people who pay attention to health and are willing to conduct hereditary tumor risk screening

Clinical Significance

For Tumor Patients

• Assists in identifying the genetic causes of tumor occurrence, providing a genetic basis for clinicians to formulate precise diagnosis and treatment plans
• Indicates tumor prognosis, and predicts the risk of the patient developing other hereditary tumors for early intervention

For People with a Family History of Tumors and the General Population

• Accurately indicates the individual risk of developing hereditary tumors, and screens out hereditary tumor high-risk groups
• Provides a scientific basis for targeted strengthening of subsequent health management, and guides high-risk groups to carry out regular early tumor screening to achieve early detection and early treatment

Standard Detection Process

1. Informed consent signing by the tested person
2. Clinical sample collection
3. Nucleic acid extraction and quality control
4. Hereditary tumor gene library preparation
5. High-throughput next generation sequencing
6. Professional bioinformatics data analysis
7. Authoritative gene variation pathogenicity interpretation (based on ACMG guidelines)
8. Formal genetic test report distribution

Lead Time